View Exam | PowerPak

1. Which statement best describes the differences between the CHADS₂ and the CHA2DS₂-VASc stroke risk scoring tools?

A. The CHADS₂score is more sensitive than the CHA₂DS₂-VASc score B. The CHA₂DS₂-VASc score accounts for risk in younger patients, aged 65-74 years C. The CHADS₂ score accounts for the increased risk of atrial fibrillation in women D. The CHA₂DS₂-VASc score accounts for alcohol use

2. A 66-year old woman with atrial fibrillation and diabetes has a calculated CHA₂DS₂-VASc risk score of 2. Which summarizes the guideline recommendations for anticoagulation therapy in this patient?

A. Her low risk score does not warrant anticoagulant therapy B. She should receive aspirin only C. She should receive anticoagulation therapy with warfarin D. She should receive anticoagulation therapy with warfarin, apixaban, dabigatran, or rivaroxaban

3. A 66-year old woman is initiated on dabigatran. At initiation of therapy, laboratory tests did not reveal any renal dysfunction. How frequently would you monitor renal function in this patient?

A. No additional monitoring is required B. Every 3 months C. Every 6 months D. Every year

4. Which statement best summarizes the results from randomized clinical trials of the novel oral anticoagulants?

A. The novel anticoagulants have reduced gastrointestinal bleeding compared with warfarin B. In head-to-head clinical trials, rivaroxaban was superior to the other novel agents for prevention of total stroke and systemic embolism C. The novel anticoagulants resulted in intracerebral hemorrhage risks comparable to warfarin D. All of the novel anticoagulants are noninferior to warfarin for prevention of total stroke and systemic embolism

5. All of the novel oral anticoagulants are partially excreted by the kidneys. Approximately 80% of which agent is excreted largely unchanged via renal pathways in healthy subjects?

A. Apixaban B. Dabigatran C. Edoxaban D. Rivaroxaban

6. In an atrial fibrillation patient receiving warfarin as anticoagulation therapy, what is the recommended strategy to convert this patient from warfarin to apixaban?

A. Start apixaban when the international normalized ratio (INR) is less than 4 B. Start apixaban when the INR is less than 3 C. Start apixaban when the INR is less than 2 D. Start apixaban when the INR is less than 1

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which statement best describes the differences between the CHADS₂ and the CHA2DS₂-VASc stroke risk scoring tools?

2. A 66-year old woman with atrial fibrillation and diabetes has a calculated CHA₂DS₂-VASc risk score of 2. Which summarizes the guideline recommendations for anticoagulation therapy in this patient?

3. A 66-year old woman is initiated on dabigatran. At initiation of therapy, laboratory tests did not reveal any renal dysfunction. How frequently would you monitor renal function in this patient?

4. Which statement best summarizes the results from randomized clinical trials of the novel oral anticoagulants?

5. All of the novel oral anticoagulants are partially excreted by the kidneys. Approximately 80% of which agent is excreted largely unchanged via renal pathways in healthy subjects?

6. In an atrial fibrillation patient receiving warfarin as anticoagulation therapy, what is the recommended strategy to convert this patient from warfarin to apixaban?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which statement best describes the differences between the CHADS2 and the CHA2DS2-VASc stroke risk scoring tools?

2. A 66-year old woman with atrial fibrillation and diabetes has a calculated CHA2DS2-VASc risk score of 2. Which summarizes the guideline recommendations for anticoagulation therapy in this patient?

3. A 66-year old woman is initiated on dabigatran. At initiation of therapy, laboratory tests did not reveal any renal dysfunction. How frequently would you monitor renal function in this patient?

4. Which statement best summarizes the results from randomized clinical trials of the novel oral anticoagulants?

5. All of the novel oral anticoagulants are partially excreted by the kidneys. Approximately 80% of which agent is excreted largely unchanged via renal pathways in healthy subjects?

6. In an atrial fibrillation patient receiving warfarin as anticoagulation therapy, what is the recommended strategy to convert this patient from warfarin to apixaban?

« Return to Activity

Customers who Purchased
this Activity also Purchased

1. Which statement best describes the differences between the CHADS₂ and the CHA2DS₂-VASc stroke risk scoring tools?

2. A 66-year old woman with atrial fibrillation and diabetes has a calculated CHA₂DS₂-VASc risk score of 2. Which summarizes the guideline recommendations for anticoagulation therapy in this patient?